SCHEMBL30523105

SCHEMBL30523105

O=C(Oc1ccc2ccccc2c1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 1.00
MAPT P10636 3/20 1.00
MEN1 O00255 3/20 1.00
TDP1 Q9NUW8 2/20 1.00
CA12 O43570 2/20 0.65
CA9 Q16790 2/20 0.65
POLB P06746 1/20 0.62
ALDH1A1 P00352 2/20 0.60
HSD17B10 Q99714 1/20 0.60
PDGFRB P09619 1/20 0.60
PDGFRA P16234 1/20 0.60
PARP10 Q53GL7 1/20 0.58
MMP1 P03956 2/20 0.55
MMP12 P39900 1/20 0.55
ESR1 P03372 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
PKM P14618 1/20 0.54
MMP2 P08253 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639878 1.00 KMT2A (1.00) KMT2AMAPTMEN1TDP1CA12
Ammonia Solution, Strong SCHEMBL11705203 0.98 KMT2A (0.96) KMT2AMAPTMEN1TDP1CA12
SCHEMBL18058690 0.96 KMT2A (0.93) KMT2AMAPTMEN1TDP1CA12
Benzoic Acid SCHEMBL9956914 0.95 KMT2A (0.90) KMT2AMAPTMEN1TDP1CA12
SCHEMBL16236876 0.92 KMT2A (0.84) KMT2AMAPTMEN1TDP1CA12
SCHEMBL16236336 0.92 KMT2A (0.84) KMT2AMAPTMEN1TDP1CA12
Betanaphthol SCHEMBL16236859 0.92 KMT2A (0.84) KMT2AMAPTMEN1TDP1CA12
SCHEMBL27267181 0.91 KMT2A (0.83) KMT2AMAPTMEN1TDP1CA12
SCHEMBL7594572 0.89 KMT2A (0.79) KMT2AMAPTMEN1TDP1CA12
SCHEMBL3911876 0.88 KMT2A (0.78) KMT2AMAPTMEN1TDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP disclosed
US-12564557-B2 Dual release dosage form capsule and methods, devices and systems for making same Gel Cap Technologies, LLC (US) 2026-03-03 US disclosed
CN-113227191-B Modified epoxy resin, epoxy resin composition, cured product, and laminate for electric/electronic circuit 三菱化学株式会社 2025-01-03 CN disclosed
EP-4480495-A2 DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME Gel Cap Technologies, LLC (US) 2024-12-25 EP disclosed
US-20240307315-A1 DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME Gel Cap Technologies, LLC (US) 2024-09-19 US disclosed
EP-3651721-B1 DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME GEL CAP TECH LLC (US) 2024-09-04 EP disclosed
US-11944707-B2 Dual release dosage form capsule and methods, devices and systems for making same Gel Cap Technologies, LLC (US) 2024-04-02 US disclosed
CN-116627007-A Electrophotographic photoreceptor, process cartridge, and image forming apparatus 富士胶片商业创新有限公司 2023-08-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564557-B2 Dual release dosage form capsule and methods, devices and systems for making same CCNA2, PDE1A, MCM2 KMT2A 3912/4885MAPT 2925/4885MEN1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.